,MD,MPH,,MD,,MD,,MS,MD,,MD,ChristianHamm,MD,MatthewPrice,MD,SergioLeonardi,MD,DianneGallup,MS,MeredithTodd,SimonaSkerjanec,PharmD,,DSc,,MD,–AdvisoryBoard:MedscapeCardiology;BoardofDirectors:BostonVAResearchInstitute,SocietyofChestPainCenters;Chair:mittee;Honoraria:AmericanCollegeofCardiology(Editor,ClinicalTrials,Cardiosource),DukeClinicalResearchInstitute(mittees),SlackPublications(ChiefMedicalEditor,CardiologyTodayIntervention),WebMD(mittees);Other:SeniorAssociateEditor,JournalofInvasiveCardiology;ResearchGrants:Amarin,AstraZeneca,Bristol-MyersSquibb,Eisai,Ethicon,Medtronic,SanofiAventis,pany;UnfundedResearch:FlowCo,PLxPharma,-labeland/orinvestigationalusesofdrugs,,intravenousglycoproteinIIb/IIIainhibitionsignificantlyreducedimportantperiproceduralischemicevents,,availableoralagentsarelimitedbytheirrelativelylongdurationofactionandbioavailability,whichmightbealiability:ifgivenpriortocoronaryangiographyandurgentoremergentCABGisdeemednecessary,insituationswhereabsorptionmaybeproblematic,suchaswithrapidtimestoPCI,inpatientswhoareintubated,nauseated,withSTEMI,,,potent,andreversible,,,butthesecondaryendpointofstentthrombosisat48hourswassignificantly
替格瑞洛的ChampionPhoenixIII期临床试验结果 (2) 来自淘豆网m.daumloan.com转载请标明出处.
